Celldex Therapeutics Inc. (CLDX)
NASDAQ: CLDXHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 30.43 0.00%
CLDX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.39B
- EPS (TTM)
- -$4.35
- Dividend yield
- None
- 52-week range
- 22.10 – 45.14
- Day range
- 30.11 – 31.35
- Volume / Avg
- 1.75M / 1.27M
- Beta
- —
- Shares outstanding
- 78.53M
- Next earnings
- Nov 9, 2026
52-week range
CLDX stock today
On Oct 7, CLDX ended the session at $30.43, shedding $0.575 (1.85%), versus the S&P 500's 0.22% decline. Shares are 32.6% below their 52-week high of $45.14, set on Aug 12, 2026 and 37.7% above the 52-week low of $22.10, in the middle of the past year's range. CLDX is up 12.0% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 16.1%.
Celldex Therapeutics has posted a net loss over the last twelve months (EPS of -$4.35), so its P/E ratio is not meaningful. Celldex Therapeutics's next earnings report is expected on Nov 9, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Celldex Therapeutics
Company profileCelldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation.
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CEO
- Mr. Anthony S. Marucci M.B.A.
- Headquarters
- Hampton, NJ
- Employees
- 198
- Website
- celldex.com
Analyst forecast
ForecastConsensus (15 analysts)
strong_buy
Avg. price target
$63.07+107.26%
- Strong buy 2
- Buy 12
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 9, 2026
Celldex Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NEOGNeogen Corporation | 11.68 | -2.34% | $2.55B | vs CLDX |
| NTLAIntellia Therapeutics Inc. | 11.71 | -5.34% | $1.64B | vs CLDX |
| QDELQuidelOrtho Corporation | 12.31 | -2.07% | $844.16M | vs CLDX |
| ACHVAchieve Life Sciences Inc. | 7.24 | +2.99% | $746.46M | vs CLDX |
| TKNOAlpha Teknova Inc. | 8.71 | -0.46% | $467.62M | vs CLDX |
| MYGNMyriad Genetics Inc. | 4.28 | 0.00% | $409.38M | vs CLDX |
| NNNNAnbio Biotechnology Class A | 4.90 | 0.00% | $215.07M | vs CLDX |
| IMDXInsight Molecular Diagnostics Inc. | 3.46 | +2.37% | $113.23M | vs CLDX |
Indexes, lists and sector
Largest Health Care stocks
Celldex Therapeutics stock FAQ
What is Celldex Therapeutics's stock price today?
CLDX last traded at $30.43 as of Oct 7, 4:00 PM EDT, down 1.85% on the day. Prices are delayed at least 15 minutes.
Does Celldex Therapeutics pay a dividend?
No. Celldex Therapeutics does not currently pay a regular cash dividend.
When is Celldex Therapeutics's next earnings date?
Celldex Therapeutics is expected to report earnings on Monday, November 9, 2026.
Who is Celldex Therapeutics's CEO?
Mr. Anthony S. Marucci M.B.A. is the chief executive officer of Celldex Therapeutics Inc., which has about 198 employees.
Has CLDX ever split its stock?
Yes. The most recent CLDX stock split was a 1-for-15 split on Feb 11, 2019, one of 2 splits on record.
What is the CLDX 52-week high?
The 52-week high for CLDX is $45.14 and the 52-week low is $22.10. The stock is currently 32.6% below its high.